Kintara Therapeutics (KTRA) has provided an update.
Kintara Therapeutics and TuHURA Biosciences announced that Kineta, Inc. has resumed enrollment for its VISTA-101 Phase 1/2 clinical trial in oncology immunotherapy. They also caution potential risks and uncertainties related to their proposed merger, including the possibility of its termination, impacts on business operations, legal challenges, and the success of the combined company. Investors are advised that forward-looking statements are not guarantees of future performance and actual results may differ, with no obligation for updates unless required by law.
For an in-depth examination of KTRA stock, go to TipRanks’ Stock Analysis page.
